ITeos Therapeutics Inc

NASDAQ:ITOS  
28.64
-0.65 (-2.22%)
Other Pre-Announcement

Iteos Therapeutics Reports Third Quarter 2020 Financial Results

Published: 11/12/2020 12:23 GMT
(ITOS) - Iteos Reports Third Quarter 2020 Financial Results and Provides Business Update.
Q3 Loss per Share $0.48.
Q3 Earnings per Share Estimate $-0.36 -- Refinitiv Ibes Data (analyst estimates).
Iteos Therapeutics - Initial Data in Phase 1/2 Studies of Eos-850 A(2a)r Antagonist and Eos-448 FcΓr-enabled Anti-tigit Antibody Expected in 1h21.
Strong Cash Position to Support Ongoing Clinical Development and Operations Into 2023.
Expects to Nominate Additional Product Candidate for Ind, Enabling Studies Before End of 2021.